Following a limited submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2017. Refer to TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | ustekinumab (Stelara®) | ||
| Formulation | 45 mg solution for injection | ||
| Reference number | 2068 | ||
| Indication | Treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Skin | ||
| Assessment type | Limited | ||
| Status | Superseded | ||
| Advice number | 0416 | ||
| NMG meeting date | 20/01/2016 | ||
| AWMSG meeting date | 24/02/2016 | ||
| Ratification by Welsh Government | 24/03/2016 | ||
| Date of issue | 01/04/2016 | ||
| NICE guidance | TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (external website - opens in new window) |
||